Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

In Vitro activity of cepfodoxime in comparison with other oral β-lactam antibiotics

In vitro-Aktivität von Cefpodoxim im Vergleich mit anderen oralen β-Laktam-Antibiotika

Summary

The aim of our study was to re-evaluate thein vitro activity of cefpodoxime in comparison with other oral β-lactam antibiotics against bacteria causing respiratory tract infections. The study drugs were cefpodoxime, cefaclor, cefixime, cefuroxime, cefetamet, cefprozil, and the combination of amoxicillin and clavulanic acid (= augmentin). In addition, cefotaxime as the standard agent of parenteral third generation cephalosporins was examined. The organisms tested wereStaphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, streptococci of serogroups C and G,Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae andProteus mirabilis. Minimal inhibitory concentrations of the antimicrobials were determined with the agar dilution procedure. Cefpodoxime showed the broadest spectrum and generally also the highest activity of the oral β-lactam antibiotics examined. The drug was equally active against the major groups of β-lactamase negative and positive bacteria causing respiratory tract infections. Against penicillin-resistant pneumococci, all β-lactam agents exhibited reduced activity comparable to the reduced activity of penicillin.

Zusammenfassung

Ziel unserer Studie war es, dieIn-vitro-Aktivität von Cefpodoxim im Vergleich mit anderen oralen β-Laktam-Antibiotika gegen häufige Erreger von Infektionen der Respirationsorgane zu untersuchen. In die Studie eingeschlossen wurden Cefaclor, Cefixim, Cefuroxim, Cefetamet, Cefprozil und die Kombination von Amoxicillin und Clavulansäure (= Augmentin). Als Repräsentativsubstanz für parenterale Cephalosporine der 3. Generation wurde das Cefotaxim mitgeführt. Geprüft wurde die Aktivität dieser Antibiotika gegenStaphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptokokken der Serogruppen C und G,Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae undProteus mirabilis. Als Aktivitätsparameter dienten die minimalen Hemmkonzentrationen (MHKs) der Prüf-Antibiotika, die mit dem Agar-Reihenverdünnungstest ermittelt wurden. Unter den oralen β-Laktam-Antibiotika wies Cefpodoxim das breiteste Spektrum und in der Regel auch die höchste Aktivität auf. Cefpodoxim war gegen alle β-Laktamase-positiven und-negativen Erreger von Infektionen der Atemwege gleich gut wirksam. Alle getesteten β-Laktam-Antibiotika wiesen geminderte Aktivität gegen Penicillin-resistente Pneumokokken auf, die in ihrem Ausmaß der reduzierten Aktivität von Penicillin gegen diese Erreger entsprach.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bauernfeind, A., Jungwirth, R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection 19 (1991) 353–362.

  2. 2.

    Chin, N.-X., Neu, H. In vitro activity of an oral iminomethoxy aminomethoxy cephalosporin, R-3746. Antimicrob. Agents Chemother. 32 (1988) 671–677.

  3. 3.

    Knothe, H., Shah, P. M., Eckhard, O. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Infection 19 (1991) 370–376.

  4. 4.

    Wiedemann, B., Luhmer, E., Zühlsdorf, M. T. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci,Enterobacteriaceae andPseudomonas aeruginosa, including β-lactamase producers. Infection 19 (1991) 363–369.

  5. 5.

    Wise, R., Andrews, J., Ashby, J., Thornber, D. Thein vitro activity of cefpodoxime: A comparison with other oral cephalosporins. J. Antimicrob. Chemother. 25 (1990) 541–550.

  6. 6.

    Kayer, F. H. Changes in the spectrum of organisms causing respiratory tract infections: a review. Postgrad. Med. J. 68 (Suppl. 3) (1992) S17-S23.

  7. 7.

    National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria which grow aerobically — 3rd ed.; Approved Standard. NCCLS document M7-A3. NCCLS, Villanova, PA 19085, 1993.

  8. 8.

    Kayser, F. H., Morenzoni, G., Santanam, P. The second European collaborative study on the frequency of antimicrobial resistance inHaemophilus influenzae. Eur. J. Clin. Microbiol. Inf. Dis. 9 (1990) 810–817.

  9. 9.

    Klugman, K. P. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3 (1990) 171–196.

  10. 10.

    Reinert, R. R., Queck, A., Kaufhold, A., Kresken, M., Lütticken, R. Antibiotic sensitivity ofStreptococcus pneumoniae isolated from normally sterile body sites: first results of a multicenter study in Germany. Infection 22 (1994) 113–114.

  11. 11.

    Wallace, R. J., Nash, D. R., Steingrube, V. A.: Antibiotic susceptibilities and drug resistance inMoraxella (Branhamella) catarrhalis. Am. J. Med. 88(5A) 46S–50S.

  12. 12.

    Pennington, J. E. Community-acquired pneumonia and acute bronchitis. In:Pennington, J. E. (ed.): Respiratory infections: diagnosis and management. 2nd. ed. Raven Press, New York 1988, pp. 159–170.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kayser, F.H. In Vitro activity of cepfodoxime in comparison with other oral β-lactam antibiotics. Infection 22, 370–375 (1994). https://doi.org/10.1007/BF01715556

Download citation

Keywords

  • Haemophilus Influenzae
  • Clavulanic Acid
  • Cefaclor
  • Cefixim
  • Cefpodoxim